Primary venous thromboembolism prophylaxis in ambulatory cancer patients;Profilaxis del tromboembolismo venoso primario en pacientes de cáncer ambulatorios

Annals of Pharmacotherapy

Volumn 47, Issue 2, 2013, Pages 198-209

  Aikens, Garrett B ^a   Rivey, Michael P ^b   Hansen, Carly J ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MONTANA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; APIXABAN; CERTOPARIN; CYCLOPHOSPHAMIDE; DALTEPARIN; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; NADROPARIN; PLACEBO; SEMULOPARIN; THALIDOMIDE; VINCRISTINE; WARFARIN;

ADVANCED CANCER; ANTICOAGULANT THERAPY; BLADDER CANCER; BLEEDING; BREAST METASTASIS; CANCER PALLIATIVE THERAPY; CANCER PATIENT; COLON CANCER; CONSOLIDATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM CANCER; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEAD AND NECK CANCER; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; INDUCTION CHEMOTHERAPY; INTERNATIONAL NORMALIZED RATIO; LIVER CANCER; LOW DRUG DOSE; LUNG CANCER; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LYMPHOMA; MEDICAL LITERATURE; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA; OVARY CANCER; PANCREAS CANCER; PATIENT MOBILITY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; RECURRENT CANCER; REVIEW; SURGICAL PATIENT; THROMBOSIS PREVENTION; UROGENITAL TRACT CANCER; UTERUS CANCER; VENOUS THROMBOEMBOLISM;

EID: 84873969237     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R335     Document Type: Review

References (55)

1. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest 2003;124:58S-68S.
2. Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumor cells. Best Pract Res Clin Haematol 2009;22:49-60.
3. Wun T, White RH. Venous thromboembolism in patients with cancer: epidemiology and risk factors. Cancer Invest 2009;27(S1):63-74.
4. Sorensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-50.
5. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632-4.
6. Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166:458-64.
7. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285-91.
8. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population based case-control study. Arch Intern Med 2000;160:809-15.
9. Cogo A, Bernardi E, Prandoni P, et al. Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch Intern Med 1994;154:164-8.
10. Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007;110:2339-46.
11. Wun T, White RH. Epidemiology of cancer-related venous thromboembolism. Best Pract Res Clin Haemotol 2009;22:9-23.
12. Otten HM, Mathijssen J, ten Cate H, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 2004;164:190-4.
13. Hussein MA. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost 2006;95:924-30.
14. Rajkumar S, Rayman S, Gertz M, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4219-23.
15. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001;98:1614-5.
16. Petrelli F, Cabiddu M, Borgonovo K, Barni S. Risk of venous and arterial thromboembolic events associated with the anti-EGFR agents: a metaanalysis of randomized clinical trials. Ann Oncol 2012;23:1672-9.
17. Deitcher SR, Gomes MP. The risk of venous thromboembolic therapy for breast carcinoma: a systemic review. Cancer 2004;101:439-49.
18. Levine MN. Adjuvant therapy and thrombosis: how to avoid the problem? Breast 2007;16 (Suppl 2):S169-S174.
19. Wun T, Law L, Harvey D, et al. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 2003;98:1514-20.
20. Khorana AA, Francis CW, Culakova E, et al. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005;104:2822-9.
21. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902-7.
22. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: prophylaxis in medical patients with enoxaparin study group. N Engl J Med 1999;341:793-800.
23. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874-9.
24. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. BMJ 2006;332: 325-9.
25. Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010;116:5377-82.
26. Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-83.
27. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-8.
28. Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2008; 84:805-10.
29. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2 suppl):e195S-226S.
30. Lyman GH, Kuderer NM. Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology guidelines. Thromb Res 2010;125(suppl 2):S120-S127.
31. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: venous thromboembolic disease, v.1.2010. www.nccn.org/ professionals/physician_gls/PDF/vte.pdf (accessed 2012 Jun 15).
32. Mandala M, Falanga A, Roila F. Venous thromboembolism in cancer patients: ESMO clinical practice guidelines for the management. Ann Oncol 2011;22(suppl 6):vi85-vi92.
33. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004;22: 1944-8.
34. Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomized, placebo-controlled, double-blind study. Lancet Oncol 2009;10:943-9.
35. Van Doormaal FF, Di Nisio M, Otten HM, et al. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 2011;29:2071-6.
36. Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012;366:601-9.
37. Kuderer NM, Khorana AA, Francis CW, et al. Low-molecular weight heparin for venous thromboprophylaxis in ambulatory cancer patients: a meta-analysis. J Clin Oncol 2009;27(15S):9537.
38. Levine MN, Gu C, Liebman HA, et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 2012;10:807-14.
39. Riess H, Pelzer U, Deutschinoff G, et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): results of the CONKO 004 trial (abstract LBA4506). J Clin Oncol 2009;27(15S).
40. Maraveyas A, Walters J, Roy R, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 2012;48:1283-92. doi: 10.1016/j.ejca.2011.10.017
41. Haas SK, Freund M, Heigener D, et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost 2012;18:159-65.
42. Chew HK, Davies AM, Wun T, et al. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 2008;6:601-8.
43. Verso M, Gussoni G, Agnelli G. Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC-2 studies. J Thromb Haemost 2010;8:1649-59.
44. Levine M, Hirsh J. Double-blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886-9.
45. Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715-22.
46. Palumbo A, Rajkumar S, Dimpoulos M, et al. Prevention of thalidomideand lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22:414-23.
47. Musallam KM, Dahdaleh FS, Shamseddine AI, Taher AT. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thromb Res 2009;123:442-52.
48. Hicks LK, Haynes AE, Reece DE, et al. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev 2008;34:442-52.
49. Niesvizky R, Martinez-Banos D, Jalbrzikowski J, et al. Prophylactic lowdose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leuk Lymphoma 2007;48:2330-7.
50. Cini M, Zamagni E, Valdre L, et al. Thalidomide-dexamethasone as upfront therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. Eur J Haem 2010;84:484-92.
51. Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 2012;119:933-9.
52. Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Onc 2011; 29:986-93.
53. Kessler P, Poul L, Gregora E, et al. Low molecular weight heparins for thromboprophylaxis during induction chemotherapy in patients with multiple myeloma. Klin Oncol 2011;24:281-6.
54. Semrad TJ, O'Donnell R, Wun T. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 2007;106: 601-8.
55. Perry JR, Julian JA, Laperriere NJ, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010;8:1959-65.